Assessment of CD133-positive extracellular membrane vesicles in pancreatic cancer ascites and beyond
- 55 Downloads
To the Editor,
In a recent publication released online (February, 25 2019; https://doi.org/10.1007/s00795-019-00218-5) in Medical Molecular Morphology and entitled “Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer”, Sakaue and colleagues propose that highly glycosylated CD133 may serve as a potential prognostic biomarker for pancreatic cancer. Their conclusions are partly based on the discrimination of CD133 immunoreactivities on Western blot . Unfortunately, essential information emerging from earlier studies that might have driven the rationale or design of the present investigation was not provided. This includes the expression of CD133 (Prominin-1) in healthy and cancerous tissues notably pancreas and, importantly, its association with extracellular membrane vesicles (EVs). Similarly, several features regarding CD133 biology, including its role in membrane dynamics and remodeling of cellular...
KeywordsBiomarker Cancer CD133 Ectosome Exosome Prominin-1
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, Ushijima T, Mihara Y, Naitou Y, Okabe Y, Kakuma T. Ohta K, Nakamura KI, Torimura T (2019) Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Med Mol Morphol. https://doi.org/10.1007/s00795-019-00218-5 (epub ahead of print) Google Scholar
- 4.Lee YJ, Wu CC, Li JW, Ou CC, Hsu SC, Tseng HH, Kao MC, Liu JY (2016) A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. Oncotarget 7(48):78499–78515Google Scholar
- 7.Karbanová J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerová H, Jászai J, Ehrmann J, Kolár Z, Liebers C, Arl S, Subrtová D, Freund D, Mokrý J, Huttner WB. Corbeil D (2008) The stem cell marker CD133 (prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 56(11):977–993CrossRefGoogle Scholar
- 10.Huttner HB, Janich P, Köhrmann M, Jászai J, Siebzehnrubl F, Blümcke I, Suttorp M, Gahr M, Kuhnt D, Nimsky C, Krex D, Schackert G, Löwenbrück K, Reichmann H, Jüttler E. Hacke W, Schellinger PD, Schwab S, Wilsch-Bräuninger M, Marzesco AM, Corbeil D (2008) The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells 26(3):698–705CrossRefGoogle Scholar
- 12.Bauer N, Wilsch-Bräuninger M, Karbanová J, Fonseca AV, Strauss D, Freund D, Thiele C, Huttner WB, Bornhäuser M, Corbeil D (2011) Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles—a role of the endocytic-exocytic pathway. EMBO Mol Med 3(7):398–409CrossRefGoogle Scholar
- 17.Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90(12):5013–5021Google Scholar
- 20.Karbanová J, Laco J, Marzesco AM, Janich P, Voborníková M, Mokrý J, Fargeas CA, Huttner WB, Corbeil D (2014) Human prominin-1 (CD133) is detected in both neoplastic and non-neoplastic salivary gland diseases and released into saliva in a ubiquitinated form. PLoS One 9(6):e98927CrossRefGoogle Scholar